Related Experiment Video
Updated: Aug 14, 2026

A Neonatal Intravenous Transplant Model for Assessment of Early-Life Immune Activities Against Cancer Cells
Published on: June 26, 2026
Two infants with life-threatening diffuse neonatal hemangiomatosis treated with cyclophosphamide
Sven Gottschling1, G Schneider, S Meyer
1Department of Pediatric Hematology and Oncology, University Children's Hospital, University of Saarland, Homburg, Germany. kisgot@uniklinik-saarland.de
Abstract:
Diffuse neonatal hemangiomatosis (DNH) is a rare, frequently fatal disorder characterized by multiple cutaneous and visceral hemangiomas. Complications include high-output cardiac failure, hemorrhage, hepatic failure, and consumption coagulopathy. We present two cases of neonates with DNH. We prescribed cyclophosphamide after failure of corticosteroids. Cyclophosphamide induced a fast regression of the lesions with no side effects in both infants. We were able to stop treatment after 3-4 courses of cyclophosphamide in both infants because of the excellent response. Cyclophosphamide seems to be a safe and effective treatment in patients suffering from life-threatening DNH unresponsive to corticosteroids.
